1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer
  4. >>Immuno-oncology

Bristol Claims A First With Opdivo In Neoadjuvant NSCLC

Co-Primary Endpoint Data May Support Early Approval

 
• By Mandy Jackson

More lung cancer patients treated with neoadjuvant Opdivo plus chemotherapy had a pathologic complete response than those who received chemo alone. BMS will discuss the results with regulators.

closeup of a young caucasian doctor man sitting at his office desk observing a chest radiograph in a tablet computer
Opdivo plus chemo had higher response rates in neoadjuvant lung cancer than chemo alone • Source: Shutterstock

Bristol Myers Squibb Company claimed an immunotherapy first on 7 October when it reported top-line results from the Phase III CheckMate-816 clinical trial, as the first company to show that a checkpoint inhibitor-based combination therapy in the neoadjuvant setting was superior to chemotherapy in a Phase III study of resectable non-small cell lung cancer.

The company reported that more NSCLC patients who received Opdivo (nivolumab) plus chemotherapy as a neoadjuvant treatment had a pathologic complete response (pCR) than NSCLC

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Immuno-oncology

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

BioNTech Aims To Diversify BNT323 Manufacturing As Filing Nears

 
• By Alaric DeArment

The company plans to expand manufacturing of the HER2-targeting ADC beyond China and plans to file for US FDA approval in 2025.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

More from Anticancer